Tiago Fauth Analyst PerformanceDirector - Equity Research Small/Mid Cap Biotechnology at Wells Fargo & CompanyTiago Fauth is a stock analyst at Wells Fargo & Company in the healthcare sector, covering 28 publicly traded companies. Over the past year, Tiago Fauth has issued 33 stock ratings, including strong buy and buy recommendations. While full access to Tiago Fauth's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Tiago Fauth's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access to unlock analyst rankings MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings83 Last 6 YearsBuy Recommendations81.82% 63 Buy RatingsCompanies Covered28 Unique Companies Ratings Distribution77RatingsDistribution of strong buy, buy, hold, and sell ratings by Tiago Fauth.RatingPercentageCount Strong Buy19.5%15 ratings Buy62.3%48 ratings Hold16.9%13 ratings Sell1.3%1 ratingsOut of 77 total stock ratings issued by Tiago Fauth at Wells Fargo & Company, the majority (62.3%) have been Buy recommendations, followed by 19.5% Strong Buy, 16.9% Hold, and 1.3% Sell.Best & Worst CallsBest Call0000.0%LQDAJun 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%TECXJan 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ28 companiesTiago Fauth, an analyst at Wells Fargo & Company, currently covers 28 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare28 companies100.0%Tiago Fauth of Wells Fargo & Company specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY23 companies82.1%PHARMACEUTICALS5 companies17.9% Tiago Fauth's Ratings History at Wells Fargo & Company Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter More filters Fewer filters Done 0 Results Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsIONSIonis Pharmaceuticals11/9/2026Reiterated Rating$31.00$54.00Outperform$0.0000.00% ROIUTHRUnited Therapeutics11/4/2026Set Price Target$607.88$720.00$0.0000.00% ROIRAPPRapport Therapeutics11/4/2026Set Price Target$25.97$73.00$0.0000.00% ROICAMPCAMP4 Therapeutics10/23/2026Initiated Coverage$3.39$10.00Strong-Buy$0.0000.00% ROIBNTCBenitec Biopharma10/23/2026Initiated Coverage$8.82$14.00Outperform$0.0000.00% ROIRAPPRapport Therapeutics10/20/2026Reiterated Rating$29.38$86.00Strong-Buy$0.0000.00% ROITNXPTonix Pharmaceuticals10/20/2026Reiterated Rating$5.92Strong-Buy$0.0000.00% ROIIONSIonis Pharmaceuticals10/20/2026Set Price Target$44.89$79.00$0.0000.00% ROIQNCXQuince Therapeutics10/9/2026Initiated Coverage$29.36$72.00Outperform$0.0000.00% ROIAVLNAvalyn Pharma10/2/2026Initiated Coverage$27.42$60.00Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. AVLNAvalyn Pharma10/2/2026Initiated Coverage$28.13$60.00Moderate Buy$0.0000.00% ROISPTXSeaport Therapeutics9/25/2026Initiated Coverage$21.12$46.00Strong-Buy$0.0000.00% ROISPTXSeaport Therapeutics9/25/2026Set Price Target$21.12$46.00$0.0000.00% ROISPTXSeaport Therapeutics9/25/2026Initiated Coverage$21.52$46.00Strong-Buy$0.0000.00% ROIRAPPRapport Therapeutics9/22/2026Reiterated Rating$41.47Strong-Buy$0.0000.00% ROIIONSIonis Pharmaceuticals9/8/2026Reiterated Rating$56.40$84.00Outperform$0.0000.00% ROIRAPPRapport Therapeutics8/17/2026Reiterated Rating$47.42$75.00Strong-Buy$0.0000.00% ROIMPLTMaplight Therapeutics8/14/2026Set Price Target$11.36$31.00$0.0000.00% ROIPLYXPolaryx Therapeutics8/13/2026Initiated Coverage$2.23$6.00Strong-Buy$0.0000.00% ROITNXPTonix Pharmaceuticals8/10/2026Reiterated Rating$12.50$27.00Strong-Buy$0.0000.00% ROITECXTectonic Therapeutic8/7/2026Lower Price Target$31.37$93.00Overweight$0.0000.00% ROIIONSIonis Pharmaceuticals7/9/2026Set Price Target$64.51$87.00$0.0000.00% ROITNXPTonix Pharmaceuticals6/24/2026Initiated Coverage$12.10$26.00Strong-Buy$0.0000.00% ROIMPLTMaplight Therapeutics6/24/2026Initiated Coverage$30.65$46.00Strong-Buy$0.0000.00% ROIMPLTMaplight Therapeutics6/24/2026Upgrade$31.96Strong-Buy$0.0000.00% ROITNXPTonix Pharmaceuticals6/24/2026Upgrade$11.98Strong-Buy$0.0000.00% ROIIONSIonis Pharmaceuticals4/10/2026Initiated Coverage$75.28$104.00Outperform$0.0000.00% ROIPTCTPTC Therapeutics4/10/2026Initiated Coverage$70.85$108.00Outperform$0.0000.00% ROIRAPPRapport Therapeutics4/10/2026Initiated Coverage$34.22$66.00Strong-Buy$0.0000.00% ROIPTCTPTC Therapeutics4/9/2026Initiated Coverage$68.69Moderate Buy$0.0000.00% ROIRAPPRapport Therapeutics4/9/2026Initiated Coverage$34.17Strong-Buy$0.0000.00% ROIIONSIonis Pharmaceuticals4/9/2026Upgrade$76.76Moderate Buy$0.0000.00% ROIINSMInsmed12/16/2025Boost Price Target$196.92$234.00Overweight$0.0000.00% ROIPTCTPTC Therapeutics11/5/2025Boost Price Target$67.72$93.00Overweight$00.0000.00% ROIINSMInsmed10/31/2025Boost Price Target$194.22$217.00Overweight$000.0000.00% ROIINSMInsmed10/20/2025Initiated Coverage$165.76$171.00Overweight$00.0000.00% ROILQDALiquidia10/20/2025Initiated Coverage$22.48$31.00Overweight$00.0000.00% ROIMNKDMannKind10/20/2025Initiated Coverage$5.47$10.00Overweight$0.0000.00% ROIPTCTPTC Therapeutics10/20/2025Initiated Coverage$65.95$73.00Overweight$00.0000.00% ROIRAREUltragenyx Pharmaceutical10/20/2025Initiated Coverage$32.63$65.00Overweight$00.0000.00% ROIPentagon magnet restrictions take effect January 1, 2027 (Ad)A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.Read the full breakdown of the proposed Army rare earth agreement and the company behind it.UTHRUnited Therapeutics10/20/2025Initiated Coverage$433.34$414.00Underweight$000.0000.00% ROIWVEWAVE Life Sciences10/20/2025Initiated Coverage$7.81$18.00Overweight$0.0000.00% ROIWVEWAVE Life Sciences9/4/2025Lower Price Target$8.00$18.00Overweight$0.0000.00% ROIINSMInsmed9/3/2025Boost Price Target$145.30$171.00Overweight$000.0000.00% ROIUTHRUnited Therapeutics9/3/2025Boost Price Target$404.27$414.00Equal Weight$000.0000.00% ROIMNKDMannKind9/3/2025Boost Price Target$5.63$10.00Overweight$0.0000.00% ROIPTCTPTC Therapeutics8/20/2025Lower Price Target$48.30$73.00Overweight$00.0000.00% ROILQDALiquidia8/13/2025Boost Price Target$24.10$31.00Overweight$00.0000.00% ROIINSMInsmed8/12/2025Boost Price Target$122.00$140.00Overweight$000.0000.00% ROIPTCTPTC Therapeutics8/8/2025Boost Price Target$46.28$79.00Overweight$00.0000.00% ROIALNYAlnylam Pharmaceuticals8/1/2025Boost Price Target$395.93$395.00Equal Weight$000.0000.00% ROIWVEWAVE Life Sciences7/31/2025Lower Price Target$8.32$21.00Overweight$0.0000.00% ROIUTHRUnited Therapeutics7/31/2025Lower Price Target$278.91$295.00Equal Weight$000.0000.00% ROIPTCTPTC Therapeutics7/29/2025Boost Price Target$48.86$78.00Overweight$00.0000.00% ROIINSMInsmed7/22/2025Boost Price Target$103.27$130.00Overweight$000.0000.00% ROIRAREUltragenyx Pharmaceutical7/10/2025Lower Price Target$30.25$65.00Overweight$00.0000.00% ROIBBIOBridgeBio Pharma6/30/2025Boost Price Target$44.24$76.00Overweight$00.0000.00% ROIALNYAlnylam Pharmaceuticals6/30/2025Boost Price Target$324.99$333.00Equal Weight$000.0000.00% ROILQDALiquidia6/12/2025Boost Price Target$14.13$25.00Overweight$00.0000.00% ROIINSMInsmed6/11/2025Boost Price Target$90.93$119.00Overweight$00.0000.00% ROISVRASavara5/28/2025Lower Price Target$2.07$7.00Overweight$0.0000.00% ROILQDALiquidia5/28/2025Boost Price Target$15.40$23.00Overweight$00.0000.00% ROIPTCTPTC Therapeutics5/27/2025Boost Price Target$45.93$74.00Overweight$00.0000.00% ROIUTHRUnited Therapeutics4/25/2025Reiterated Rating$296.42$314.00Equal Weight$000.0000.00% ROIALNYAlnylam Pharmaceuticals3/21/2025Boost Price Target$253.60$287.00Equal Weight$000.0000.00% ROITECXTectonic Therapeutic3/21/2025Lower Price Target$20.58$101.00Overweight$00.0000.00% ROIPLRXPliant Therapeutics3/4/2025Lower Price Target$1.38$3.00Equal Weight$0.0000.00% ROIKROSKeros Therapeutics2/27/2025Lower Price Target$11.35$26.00Overweight$00.0000.00% ROIFOLDAmicus Therapeutics2/20/2025Lower Price Target$9.56$17.00Overweight$00.0000.00% ROIINSMInsmed2/19/2025Boost Price Target$81.36$107.00Overweight$000.0000.00% ROIPLRXPliant Therapeutics2/10/2025Downgrade$7.79$4.00Equal Weight$0.0000.00% ROITECXTectonic Therapeutic1/31/2025Boost Price Target$59.23$112.00Overweight$00.0000.00% ROILQDALiquidia12/20/2024Initiated Coverage$10.59$20.00Overweight$00.0000.00% ROIMNKDMannKind12/20/2024Initiated Coverage$6.30$9.00Overweight$0.0000.00% ROISVRASavara12/20/2024Initiated Coverage$3.23$8.00Overweight$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche BankBMO Capital Markets Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.